Search results for "NAV"

showing 10 items of 2523 documents

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19☆

2020

Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-C…

0301 basic medicinemedicine.medical_specialtyVitamina Cmedicine.drug_classLung injurymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineOzoneIntensive caremedicineAdjuvant therapyVitamin CIntensive care medicineOzonoCoronavirusbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicineGeneral MedicineAscorbic acidmedicine.diseaseClinical trialPneumonia030104 developmental biologyAntiviral drugbusinessRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

2020

This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosp…

0301 basic medicinemedicine.medical_specialtyvirusesmedicine.medical_treatmentHepatitis C viruscoronavirusReviewBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyVirusOrgan transplantation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRotavirusmedicinecyclosporineinfectionstacrolimuslcsh:QH301-705.5Coronavirushuman papilloma virus infectionGeneral Immunology and MicrobiologyHepatitis Cmedicine.diseasecalcineurin inhibitorshuman herpesvirusVirologyTacrolimusAIDShepatitis flu030104 developmental biologyImmunosuppressive druglcsh:Biology (General)cyclophilinGeneral Agricultural and Biological SciencesBiology
researchProduct

Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers

2017

Immunotherapies have the potential to significantly advance treatment of inflammatory disease and cancer, which are in large part driven by immune cells. Selectins control the first step in immune cell adhesion and extravasation, thereby guiding leukocyte trafficking to tissue lesions. We analyzed four different highly specific selectin-binding glycopolymers, based on linear poly(2-hydroxypropyl)-methacrylamide (PHPMA) polymers. These glycopolymers contain either the tetrasaccharide sialyl-LewisX (SLeX) or the individual carbohydrates fucose, galactose, and sialic acids mimicking the complex SLeX binding motive. The glycopolymers strongly bind to primary human macrophages, without activatin…

0301 basic medicinemedicine.medical_treatmentGeneral Physics and Astronomy02 engineering and technologyFucoseImmunomodulationMice03 medical and health scienceschemistry.chemical_compoundImmune systemPolysaccharidesmedicineAnimalsHumansGeneral Materials ScienceCell adhesionCells CulturedInflammationBinding SitesbiologyChemistryLiver DiseasesGeneral EngineeringImmunotherapy021001 nanoscience & nanotechnologyDynamic Light ScatteringExtravasationIn vitro3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologyBiochemistryConcanavalin ASelectinsbiology.proteinCancer researchCytokines0210 nano-technologySelectinACS Nano
researchProduct

Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection

2021

Apart from prevention using vaccinations, the management options for COVID-19 remain limited. In retrospective cohort studies, use of famotidine, a specific oral H2 receptor antagonist (antihistamine), has been associated with reduced risk of intubation and death in patients hospitalized with COVID-19. In a case series, nonhospitalized patients with COVID-19 experienced rapid symptom resolution after taking famotidine, but the molecular basis of these observations remains elusive. Here we show using biochemical, cellular, and functional assays that famotidine has no effect on viral replication or viral protease activity. However, famotidine can affect histamine-induced signaling processes i…

0301 basic medicinemedicine.medical_treatmentPharmacologyVirus ReplicationBiochemistrychemistry.chemical_compoundChemokine CCL2Coronavirus 3C ProteasesResearch ArticlesToll-like receptorbiologyNF-kappa BFamotidineMolecular Docking SimulationCytokine release syndromeCytokinemedicine.symptomSignal transductionHistaminemedicine.drugProtein BindingSignal TransductionHistamine AntagonistsInflammation03 medical and health sciencesToll-like receptormedicineHumansInterleukin 6Molecular BiologyBinding Sites030102 biochemistry & molecular biologybusiness.industryInterleukin-6SARS-CoV-2Cell Biologymedicine.diseasehistamineToll-Like Receptor 3Famotidine030104 developmental biologychemistryA549 CellsSARS-CoV2biology.proteinanti-viral signalingInterferon Regulatory Factor-3Caco-2 CellsbusinessHeLa Cells
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

Statistical Explorations and Univariate Timeseries Analysis on COVID-19 Datasets to Understand the Trend of Disease Spreading and Death

2020

&ldquo

0301 basic medicinetransmission ratepopulationSevere Acute Respiratory Syndromemedicine.disease_causelcsh:Chemical technologyBiochemistryRNNDisease OutbreaksAnalytical Chemistry0302 clinical medicinePandemiclcsh:TP1-1185030212 general & internal medicineInstrumentationVDP::Teknologi: 500::Informasjons- og kommunikasjonsteknologi: 550Coronaviruskeraseducation.field_of_studypublic healthartificial intelligenceAtomic and Molecular Physics and OpticsRegressionmachine learningGeographySevere acute respiratory syndrome-related coronavirusstatisticsMiddle East Respiratory Syndrome Coronaviruscommunity diseaseregressionCoronavirus InfectionsLSTMPneumonia ViralPopulationWorld Health OrganizationArticleBetacoronavirusspread factor03 medical and health sciencesCode (cryptography)medicineAnimalsHumansElectrical and Electronic EngineeringeducationPandemicsmeasurable sensor dataalgorithmSARS-CoV-2ICDUnivariatedeep learningOutbreakCOVID-19medicine.diseasehypothesis testpython030104 developmental biologycorrelationCatsMiddle East respiratory syndromeCattleDemographySensors
researchProduct

Beyond malaria: The inhibition of viruses by artemisinin-type compounds

2018

Abstract Natural products represent valuable chemical scaffolds for drug development. A recent success story in this context was artemisinin, which is not only active against malaria but also to other diseases. This raised the interest of artemisinin's potential for drug repurposing. On the present review, we give an overview on artemisinin's antiviral activity. There is good in vitro and in vivo evidence for the activity of artemisinin and its derivatives against DNA viruses of the Herpesviridae and Hepadnaviridae families such as cytomegaloviruses, human herpesvirus 6, herpes simplex viruses 1 and 2, Epstein-Barr virus and Hepatitis B virus. The evidence is weaker for Polyomaviruses and p…

0301 basic medicinevirusesPhytochemicalsArtemisia annuaBioengineeringmedicine.disease_causeAntiviral AgentsApplied Microbiology and BiotechnologyVirusHerpesviridae03 medical and health scienceschemistry.chemical_compoundparasitic diseasesmedicineAnimalsHumansRNA VirusesArtemetherArtemisininHepatitis B virusbiologyDNA Virusesbiology.organism_classificationVirologyArtemisinins030104 developmental biologychemistryHepadnaviridaeVirus DiseasesArtesunateBiotechnologymedicine.drugBiotechnology Advances
researchProduct

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.

2021

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic the…

030213 general clinical medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationGuidelineGuidelinesGlobal HealthAntiviral AgentsPatient pathwaySimplification03 medical and health sciences0302 clinical medicinePandemicGlobal healthMedicineHumansPharmacology (medical)Disease EradicationIntensive care medicineAntiviral Agentbusiness.industrySARS-CoV-2Public healthCOVID-19General MedicineHepatitis CHcv eliminationClinical trialCritical Pathway030220 oncology & carcinogenesisCommunicable Disease ControlPractice Guidelines as TopicKey (cryptography)Critical PathwaysCommentarybusinessHumanAdvances in therapy
researchProduct

The first wave of the Spanish COVID-19 epidemic was associated with early introductions and fast spread of a dominating genetic variant

2020

The COVID-19 pandemic has shaken the world since the beginning of 2020. Spain is among the European countries with the highest incidence of the disease during the first pandemic wave. We established a multidisciplinar consortium to monitor and study the evolution of the epidemic, with the aim of contributing to decision making and stopping rapid spreading across the country. We present the results for 2170 sequences from the first wave of the SARS-Cov-2 epidemic in Spain and representing 12% of diagnosed cases until 14th March. This effort allows us to document at least 500 initial introductions, between early February-March from multiple international sources. Importantly, we document the …

0303 health sciences03 medical and health sciences2019-20 coronavirus outbreak0302 clinical medicineGeographyCoronavirus disease 2019 (COVID-19)Research councilSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Genetic variantsLibrary science030212 general & internal medicine030304 developmental biology3. Good health
researchProduct